Excess sugar consumption triggers inflammation and dysbiosis, worsening periodontal disease

Research explores how excessive sugar consumption can drive systemic inflammation, disrupt the gut and oral microbiomes, and contribute to periodontal inflammation, with implications for global health.

J&J targets generalised myasthenia gravis landscape with nipocalimab – Pharmaceutical Technology

Nipocalimab is an IgG receptor FcRn large subunit p51 antagonist designed to compete with IgG in binding to FcRn. Credits: Skorzewiak/Shutterstock.com Johnson & Johnson (J&J)

August 30, 2024

U.S. cardiovascular disease costs set to skyrocket by 2050, new study reveals

New research forecasts that the economic burden of cardiovascular disease and stroke in the U.S. will nearly quadruple by 2050, highlighting the urgent need for

June 6, 2024

FemTech: Flo Health Secures $200M for Women’s Health Platform

What You Should Know: – Flo Health, the world’s leading women’s health app raises $200M in Series C funding from General Atlantic. This investment propels

July 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.